Synonyms: CP-70,429 | CP-70429 | CP70429
Compound class:
Synthetic organic
Comment: Sulopenem is a β-lactam (carbapenem) antibacterial [3]. It has a broad-spectrum of activity against Gram-negative, Gram-positive and anaerobic bacteria, including multi-drug resistant Gram-negative infections in both the hospital and community settings. Sulopenem is relatively stable against hydrolysis by various β-lactamases. It is being developed for oral and parenteral administration.
|
|
No information available. |
Summary of Clinical Use |
Oral and i.v. sulopenem are being evaluated in three pivotal Phase 3 clinical trials of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra-abdominal infections (cIAI). All of these trials have been completed. Updates released online (in late 2019) indicate that the drug narrowly missed its primary endpoint in the cIAI study [5]. Results from the UTI studies have been posted with ClinicalTrials.gov. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03354598 | Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women | Phase 3 Interventional | Iterum Therapeutics, International Limited | ||
NCT03357614 | Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults | Phase 3 Interventional | Iterum Therapeutics, International Limited | 1 | |
NCT03358576 | Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI) | Phase 3 Interventional | Iterum Therapeutics, International Limited |